Title

Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome.

Document Type

Article

Publication Date

10-3-2016

Comments

This article has been peer reviewed. It was published in: Oman journal of ophthalmology.

Volume 9, Issue 3, October 2016, Pages 164-166.

The published version is available at DOI: 10.4103/0974-620X.192278

Copyright © 2016 Oman Ophthalmic Society

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Abstract

Two infants with retinoblastoma and 13q syndrome with multiorgan system anomalies were treated with targeted intra-arterial chemotherapy (IAC) using one-to-three cycles of melphalan 5 mg to avoid systemic chemotherapeutic side effects. Both patients showed good response, with tumor control and no systemic chemotherapy side effects. Of the treatment modalities currently available, IAC may represent an optimal balance between tumor extermination and adverse drug reactions in this patient population with classically reduced multiorgan reserve.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.